Quest PharmaTech formed a strategic alliance with IntelligentNano and through this new partnership the companies have developed a water soluble nano-formulation of Quest's SL052 technology. The second generation drug delivery system will expand the technology's reach past cancer treatment to other diseases of the body.
The alliance was reportedly created to explore IntelligentNano's nanotechnology as a means of enhancing the biocompatible drug delivery systems for clinical applications of Quest's SonoLight technology platform.
"The fulfillment of a second tier of targetable, water-soluble nano-formulations of the SonoLight compounds represents major progress in the adaptation of Hypocrellin-based photodynamic and sonodynamic therapy to a wide spectrum of clinical needs including cancer treatment," says Madi R. Madiyalakan, Ph.D, CEO at Quest.
Quest's current SonoLight photosensitizer and sonosensitizer formulations are based upon liposomal drug delivery systems. The company says it intends to initiate a series of preclinical studies with these new formulations and arrive at a clinical plan for Quest's second cancer indication.
Quest also intends to initiate a Phase I trial for SL052 as a localized treatment for prostate cancer.